The company is committed to introduce into market both innovative biomedical devices supporting the isolation and expansion of cells for pre-clinical and clinical applicationsand cell/gene therapy products with a main focus in cancer

Founded back in 2009 as a spin-off resulting from a joint venture between the biomedical company RanD and researchers from the University of Modena and Reggio Emilia, in 2016 Rigenerand was funded by Principia SGR which allowed investments in new technologies and the realization of a 500 sqm cell factory for the development of cell-based products

Rigenerand has two divisions one developing and manufacturing biodisposables – Rignerand BioDi – for therapeutic and diagnostic applications and one developing gene therapy programs for solid tumors – Rignerand Thera

Our Philosophy: Filling Techologicaland Therapeutics Gaps

Rigenerand wants to develop and produce innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology.
Our philosophy is driven by the need to fill gaps in cell manufacturing based on novel biomedical devices that conjugate safety, low cost of manufacturing and a progressive automation. Simultaneously, Rigenerand aims to fill therapeutics gaps for still incurable cancers, such as pancreatic adenocarcinoma, by manufacturing smart treatments based on gene-modified effectors redirected against cancer.

MainProducts

Rignerand BioDi develops and produces technologies for ex-vivo application of human cells for diagnostics and therapeutics

Rignerand Thera generates products based on gene-modified effector cells for cancer treatments

Partners

MoreInfo?

CONTACT US

Meet the Team

DISCOVER THE TEAM